Skip to main content
Erschienen in: Neurological Sciences 1/2010

01.02.2010 | Original Article

Concordance between severity of disease, disability and health-related quality of life in Myasthenia gravis

verfasst von: Alberto Raggi, Matilde Leonardi, Carlo Antozzi, Paolo Confalonieri, Lorenzo Maggi, Ferdinando Cornelio, Renato Mantegazza

Erschienen in: Neurological Sciences | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Aim of this study is to verify whether there is concordance between disease’s severity, health-related quality of life (HRQoL) and disability in patients with Myasthenia gravis (MG). 102 MG patients were clustered on the basis of HRQoL and disability scores into three groups: low disability and low HRQoL decrement (51 patients), intermediate disability and HRQoL decrement (28 patients), severe disability and high HRQoL decrement (23 patients). Cross tabulation with symmetric measures (Cramer’s V and Contingency Coefficient) was used to verify the relationships between disease severity groups, based on the Myasthenia Gravis Foundation of America (MGFA) criteria, and obtained clusters. Results confirm a significant relationship between MG severity groups, HRQoL and disability profiles. In our opinion, HRQoL and disability instruments should be employed in clinical trials to match efficacy of treatments, measured on symptoms’ reductions only, with their effects on patients’ disability and HRQoL.
Literatur
1.
Zurück zum Zitat Conti-Fine BM, Milani M, Kaminski HJ (2006) Myasthenia gravis: past, present, future. J Clin Invest 116:2843–2854CrossRefPubMed Conti-Fine BM, Milani M, Kaminski HJ (2006) Myasthenia gravis: past, present, future. J Clin Invest 116:2843–2854CrossRefPubMed
2.
Zurück zum Zitat Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16–23PubMed Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16–23PubMed
3.
4.
Zurück zum Zitat Mantegazza R, Baggi F, Antozzi C, Confalonieri P, Morandi L, Bernasconi P, Andreetta F, Simoncini O, Campanella A, Beghi E, Cornelio F (2003) Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann N Y Acad Sci 998:413–423CrossRefPubMed Mantegazza R, Baggi F, Antozzi C, Confalonieri P, Morandi L, Bernasconi P, Andreetta F, Simoncini O, Campanella A, Beghi E, Cornelio F (2003) Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann N Y Acad Sci 998:413–423CrossRefPubMed
5.
Zurück zum Zitat Barohn RJ, Mcintire D, Herbelin L, Wolfe GI, Nations S, Bryan W (1998) Reliability testing of the quantitative myasthenia gravis score. Ann NY Acad Sci 941:769–772CrossRef Barohn RJ, Mcintire D, Herbelin L, Wolfe GI, Nations S, Bryan W (1998) Reliability testing of the quantitative myasthenia gravis score. Ann NY Acad Sci 941:769–772CrossRef
6.
Zurück zum Zitat Pauda L, Evoli A, Aprile I, Caliandro P, Mazza S, Padua R, Tonali P (2001) Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci 22:363–369CrossRef Pauda L, Evoli A, Aprile I, Caliandro P, Mazza S, Padua R, Tonali P (2001) Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci 22:363–369CrossRef
7.
Zurück zum Zitat Paul RH, Nash J, Cohen RA, Gilchrist JM, Goldstein JM (2001) Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve 24:512–516CrossRefPubMed Paul RH, Nash J, Cohen RA, Gilchrist JM, Goldstein JM (2001) Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve 24:512–516CrossRefPubMed
8.
Zurück zum Zitat Padua L, Evoli A, Aprile I, Caliandro P, D’Amico P, Rabini A, Tonali P (2002) Quality of life in patients with myasthenia gravis. Muscle Nerve 25:466–467CrossRefPubMed Padua L, Evoli A, Aprile I, Caliandro P, D’Amico P, Rabini A, Tonali P (2002) Quality of life in patients with myasthenia gravis. Muscle Nerve 25:466–467CrossRefPubMed
9.
Zurück zum Zitat Rostedt A, Padua L, Stålberg EV (2006) Correlation between regional myasthenic weakness and mental aspects of quality of life. Eur J Neurol 13:191–193CrossRefPubMed Rostedt A, Padua L, Stålberg EV (2006) Correlation between regional myasthenic weakness and mental aspects of quality of life. Eur J Neurol 13:191–193CrossRefPubMed
10.
Zurück zum Zitat Rostedt A, Padua L, Stalberg EV (2005) Correlation between a patient-derived functional questionnaire and abnormal neuromuscular transmission in Myasthenia Gravis patients. Clin Neurophysiol 116:2058–2064CrossRefPubMed Rostedt A, Padua L, Stalberg EV (2005) Correlation between a patient-derived functional questionnaire and abnormal neuromuscular transmission in Myasthenia Gravis patients. Clin Neurophysiol 116:2058–2064CrossRefPubMed
11.
Zurück zum Zitat Scott KR, Kothari MJ (2006) Self-reported pain affects quality of life in Myasthenia Gravis. J Clin Neuromusc Dis 7:110–114CrossRef Scott KR, Kothari MJ (2006) Self-reported pain affects quality of life in Myasthenia Gravis. J Clin Neuromusc Dis 7:110–114CrossRef
12.
Zurück zum Zitat Happe S, Klosch G, Zeitlhofer J (2004) Perception of dreams and subjective sleep quality in patients with myasthenia gravis. Neuropsychobiology 50:21–27CrossRefPubMed Happe S, Klosch G, Zeitlhofer J (2004) Perception of dreams and subjective sleep quality in patients with myasthenia gravis. Neuropsychobiology 50:21–27CrossRefPubMed
13.
Zurück zum Zitat Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, Melms A, Nicolle MW, Solomons N, Richman DP (2008) An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 71:400–406CrossRefPubMed Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, Melms A, Nicolle MW, Solomons N, Richman DP (2008) An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 71:400–406CrossRefPubMed
14.
Zurück zum Zitat Rostedt A, Padua L, Stalberg EV (2006) Validation of the Swedish version of the disease-specific Myasthenia Gravis Questionnaire. Neurol Sci 27:91–96CrossRefPubMed Rostedt A, Padua L, Stalberg EV (2006) Validation of the Swedish version of the disease-specific Myasthenia Gravis Questionnaire. Neurol Sci 27:91–96CrossRefPubMed
15.
Zurück zum Zitat Padua L, Galassi G, Ariatti A, Aprile I, Caliandro P, Evoli A, Pazzaglia C, Tonali P (2005) Myasthenia gravis self-administered questionnaire: development of regional domains. Neurol Sci 25:331–336CrossRefPubMed Padua L, Galassi G, Ariatti A, Aprile I, Caliandro P, Evoli A, Pazzaglia C, Tonali P (2005) Myasthenia gravis self-administered questionnaire: development of regional domains. Neurol Sci 25:331–336CrossRefPubMed
16.
Zurück zum Zitat Mullins LL, Carpentier MY, Paul RH, Sanders DB, Muscle Study Group (2008) Disease-specific measure of quality of life for Myasthenia Gravis. Muscle Nerve 38:947–956CrossRefPubMed Mullins LL, Carpentier MY, Paul RH, Sanders DB, Muscle Study Group (2008) Disease-specific measure of quality of life for Myasthenia Gravis. Muscle Nerve 38:947–956CrossRefPubMed
17.
Zurück zum Zitat Burns TM, Conaway MR, Cutter GR, Sanders DB, Muscle Study Group (2008) Less is more, or almost as much: a 15-item quality of life instrument for myasthenia gravis. Muscle Nerve 38:957–963CrossRefPubMed Burns TM, Conaway MR, Cutter GR, Sanders DB, Muscle Study Group (2008) Less is more, or almost as much: a 15-item quality of life instrument for myasthenia gravis. Muscle Nerve 38:957–963CrossRefPubMed
18.
Zurück zum Zitat Leonardi M, Bickenbach J, Ustun TB, Kostanjsek N, Chatterji S, MHADIE Consortium (2006) The definition of disability: what is in a name? Lancet 368:1219–1221CrossRefPubMed Leonardi M, Bickenbach J, Ustun TB, Kostanjsek N, Chatterji S, MHADIE Consortium (2006) The definition of disability: what is in a name? Lancet 368:1219–1221CrossRefPubMed
19.
Zurück zum Zitat World Health Organisation (2001) The international classification of functioning, disability and health-ICF. WHO, Geneva World Health Organisation (2001) The international classification of functioning, disability and health-ICF. WHO, Geneva
20.
Zurück zum Zitat Apolone G, Mosconi P (1998) The Italian SF-36 health survey: translation, validation and norming. J Clin Epidemiol 51:1025–1036CrossRefPubMed Apolone G, Mosconi P (1998) The Italian SF-36 health survey: translation, validation and norming. J Clin Epidemiol 51:1025–1036CrossRefPubMed
21.
Zurück zum Zitat Ustun TB (1999) WHO-DAS II Field Trials Report 1998. WHO, Geneva Ustun TB (1999) WHO-DAS II Field Trials Report 1998. WHO, Geneva
22.
Zurück zum Zitat Bedlack RS, Simel DL, Bosworth H, Samsa B, Tucker-Lipscomb B, Sanders DB (2005) Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 64:1968–1970CrossRefPubMed Bedlack RS, Simel DL, Bosworth H, Samsa B, Tucker-Lipscomb B, Sanders DB (2005) Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 64:1968–1970CrossRefPubMed
23.
Zurück zum Zitat Mantegazza R, Antozzi C, Peluchetti D, Sghirlanzoni A, Cornelio F (1988) Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 255:449–453CrossRef Mantegazza R, Antozzi C, Peluchetti D, Sghirlanzoni A, Cornelio F (1988) Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 255:449–453CrossRef
24.
Zurück zum Zitat Sharshar T, Chevret S, Mazighi M, Chillet P, Huberfeld G, Berreotta C, Houfani M, Gajdos P (2000) Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis. J Neurol 247:286–290CrossRefPubMed Sharshar T, Chevret S, Mazighi M, Chillet P, Huberfeld G, Berreotta C, Houfani M, Gajdos P (2000) Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis. J Neurol 247:286–290CrossRefPubMed
25.
Zurück zum Zitat Wolfe GI, Herbelin LR, Nations SP, Foster B, Bryan WW, Barohn RJ (1999) Myasthenia gravis activities of daily living profile. Neurology 52:1487–1489PubMed Wolfe GI, Herbelin LR, Nations SP, Foster B, Bryan WW, Barohn RJ (1999) Myasthenia gravis activities of daily living profile. Neurology 52:1487–1489PubMed
26.
Zurück zum Zitat Vanderveldea L, Van den Bergh PYK, Goemans N, Thonnard JL (2007) ACTIVLIM: a Rash-built measure of activity limitations in children and adults with neuromuscular disorders. Neuromuscul Disord 17:459–469CrossRef Vanderveldea L, Van den Bergh PYK, Goemans N, Thonnard JL (2007) ACTIVLIM: a Rash-built measure of activity limitations in children and adults with neuromuscular disorders. Neuromuscul Disord 17:459–469CrossRef
Metadaten
Titel
Concordance between severity of disease, disability and health-related quality of life in Myasthenia gravis
verfasst von
Alberto Raggi
Matilde Leonardi
Carlo Antozzi
Paolo Confalonieri
Lorenzo Maggi
Ferdinando Cornelio
Renato Mantegazza
Publikationsdatum
01.02.2010
Verlag
Springer Milan
Erschienen in
Neurological Sciences / Ausgabe 1/2010
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-009-0167-y

Weitere Artikel der Ausgabe 1/2010

Neurological Sciences 1/2010 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.